A 56-year-old cisgender man with HIV and diabetes mellitus is seen for routine follow-up. He is taking an antiretroviral regimen that consists of dolutegravir, doravirine, and darunavir-cobicistat-tenofovir alafenamide-emtricitabine. A recent fasting lipid panel shows total cholesterol of 257 mg/dL, low-density lipoprotein level (LDL) cholesterol of 142 mg/dL, high-density lipoprotein level (HDL) cholesterol of 33 mg/dL, and triglycerides of 231 mg/dL. He has made a major effort to improve his diet during the past 6 months, but this did not result in a significant change in the lipid panel. He is a nonsmoker and has no family history of cardiovascular disease.